EPIGENOMICS AG (ECX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ECX - DE000A37FT41 - Common Stock
0.7 EUR
-0.09 (-11.17%)
ECX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. ECX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ECX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
ECX had negative earnings in the past year.
In the past year ECX has reported a negative cash flow from operations.
In the past 5 years ECX always reported negative net income.
In the past 5 years ECX always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -386.29%, ECX is not doing good in the industry: 92.00% of the companies in the same industry are doing better.
ECX has a Return On Equity of -853.33%. This is in the lower half of the industry: ECX underperforms 73.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -386.29% | ||
| ROE | -853.33% | ||
| ROIC | N/A |
ROA(3y)-85.87%
ROA(5y)-87.49%
ROE(3y)-143.87%
ROE(5y)-135.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ECX has a better Gross Margin (76.56%) than 78.67% of its industry peers.
ECX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ECX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.98%
GM growth 5Y-2.81%
2. Health
2.1 Basic Checks
ECX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ECX has more shares outstanding than it did 1 year ago.
The debt/assets ratio for ECX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -44.22, we must say that ECX is in the distress zone and has some risk of bankruptcy.
ECX has a worse Altman-Z score (-44.22) than 93.33% of its industry peers.
ECX has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
ECX's Debt to Equity ratio of 0.06 is fine compared to the rest of the industry. ECX outperforms 73.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -44.22 |
ROIC/WACCN/A
WACC3.9%
2.3 Liquidity
A Current Ratio of 1.93 indicates that ECX should not have too much problems paying its short term obligations.
The Current ratio of ECX (1.93) is comparable to the rest of the industry.
ECX has a Quick Ratio of 1.93. This is a normal value and indicates that ECX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ECX (1.93) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
ECX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -7359.64%.
The Revenue for ECX has decreased by -92.80% in the past year. This is quite bad
ECX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -23.61% yearly.
EPS 1Y (TTM)-7359.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3779.63%
Revenue 1Y (TTM)-92.8%
Revenue growth 3Y-24.46%
Revenue growth 5Y-23.61%
Sales Q2Q%-44.44%
3.2 Future
ECX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.99% yearly.
Based on estimates for the next years, ECX will show a very strong growth in Revenue. The Revenue will grow by 108.06% on average per year.
EPS Next Y47.75%
EPS Next 2Y39.12%
EPS Next 3Y25.12%
EPS Next 5Y17.99%
Revenue Next Year2136.83%
Revenue Next 2Y-36.75%
Revenue Next 3Y-25.99%
Revenue Next 5Y108.06%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ECX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ECX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ECX's earnings are expected to grow with 25.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.12%
EPS Next 3Y25.12%
5. Dividend
5.1 Amount
ECX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:ECX (6/27/2024, 7:00:00 PM)
0.7
-0.09 (-11.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap23.90K
Revenue(TTM)448.00K
Net Income(TTM)-16.29M
Analysts80
Price Target16.32 (2231.43%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.6%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.05 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.01 | ||
| P/tB | 0.01 | ||
| EV/EBITDA | N/A |
EPS(TTM)-17.68
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-397.44
FCFYN/A
OCF(TTM)-367.27
OCFYN/A
SpS13.12
BVpS55.92
TBVpS54.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -386.29% | ||
| ROE | -853.33% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.56% | ||
| FCFM | N/A |
ROA(3y)-85.87%
ROA(5y)-87.49%
ROE(3y)-143.87%
ROE(5y)-135.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.98%
GM growth 5Y-2.81%
F-Score3
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 46.27% | ||
| Cap/Sales | 229.91% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z | -44.22 |
F-Score3
WACC3.9%
ROIC/WACCN/A
Cap/Depr(3y)64.84%
Cap/Depr(5y)50.54%
Cap/Sales(3y)94.83%
Cap/Sales(5y)60.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7359.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3779.63%
EPS Next Y47.75%
EPS Next 2Y39.12%
EPS Next 3Y25.12%
EPS Next 5Y17.99%
Revenue 1Y (TTM)-92.8%
Revenue growth 3Y-24.46%
Revenue growth 5Y-23.61%
Sales Q2Q%-44.44%
Revenue Next Year2136.83%
Revenue Next 2Y-36.75%
Revenue Next 3Y-25.99%
Revenue Next 5Y108.06%
EBIT growth 1Y-157.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.62%
EBIT Next 3Y25.99%
EBIT Next 5Y-7.05%
FCF growth 1Y-63.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.5%
OCF growth 3YN/A
OCF growth 5YN/A
EPIGENOMICS AG / ECX.DE FAQ
What is the ChartMill fundamental rating of EPIGENOMICS AG (ECX.DE) stock?
ChartMill assigns a fundamental rating of 2 / 10 to ECX.DE.
What is the valuation status of EPIGENOMICS AG (ECX.DE) stock?
ChartMill assigns a valuation rating of 1 / 10 to EPIGENOMICS AG (ECX.DE). This can be considered as Overvalued.
Can you provide the profitability details for EPIGENOMICS AG?
EPIGENOMICS AG (ECX.DE) has a profitability rating of 1 / 10.
What is the earnings growth outlook for EPIGENOMICS AG?
The Earnings per Share (EPS) of EPIGENOMICS AG (ECX.DE) is expected to grow by 47.75% in the next year.